Effect of Servo-Ventilation on CO2 Regulation and Heart Rate Variability
NCT ID: NCT03890939
Last Updated: 2019-05-09
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE4
Total Enrollment
50 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-07-15
Study Completion Date
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) is a condition where the upper airway partially collapses and closes. This can lead to sleep problems including low oxygen levels, poor sleep, elevated carbon dioxide levels in the blood, and activation of the sympathetic nervous system. Results from having disrupted sleep may be excessive daytime sleepiness along with behavioral, functional, cardiovascular and cognitive dysfunction. Continuous Positive Airway Pressure (CPAP) is the most effective treatment for OSAHS. CPAP stabilizes the airway and prevents instability and collapse. Other forms of positive airway pressure that are approved for the treatment of OSAHS include automatically adjusting CPAP, Bi-level Positive Airway Pressure (BiPAP), and automatically adjusting BiPAP. Automatically adjusting CPAP (Auto CPAP) evaluates the airflow pattern and adjusts pressure to optimize airflow. AutoSV (Auto Servo Ventilation) is a mode of positive airway pressure used to treat obstructive and complex central sleep apnea.
In the prior study, the investigators found that the Auto S7 device led to more positive ventilation outcomes. Specifically, there was prolongation of QTc interval (the calculated time from the Q wave to the end of the T wave) and a tendency for greater premature ventricular contractions. The mechanistic basis for this could be attributable to excessive ventilation and related pro-arrhythmic effects of hypocapnia, though the investigators had not performed measures (partial pressure of CO2 (PaCO2) to detect this.
In the current study, the investigators would like to investigate the hypothesis that the S7 device leads to lower PaCO2 levels than other devices, and whether these effects are augmented in individuals with complex sleep apnea in the setting of systolic heart failure.
In the prior study, the investigators found that the Auto S7 device led to more positive ventilation outcomes. Specifically, there was prolongation of QTc interval (the calculated time from the Q wave to the end of the T wave) and a tendency for greater premature ventricular contractions. The mechanistic basis for this could be attributable to excessive ventilation and related pro-arrhythmic effects of hypocapnia, though the investigators had not performed measures (partial pressure of CO2 (PaCO2) to detect this.
In the current study, the investigators would like to investigate the hypothesis that the S7 device leads to lower PaCO2 levels than other devices, and whether these effects are augmented in individuals with complex sleep apnea in the setting of systolic heart failure.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Adaptive Servo Ventilation and Oxygen Therapy in Central Sleep Apnea Patients
NCT01187823
Chronic Heart Failure
Sleep Apnea
COMPLETED
NA
Evaluation of the Philips Respironics BiPAP autoSV Devices in Subjects With Sleep Disorders
NCT01626989
Sleep Disordered Breathing
Sleep Apnea, Central
COMPLETED
NA
Registry on the Treatment of Central and Complex Sleep-Disordered Breathing With Adaptive Servo-Ventilation
NCT03032029
Central Sleep Apnea
Complex Sleep Apnea
Obstructive Sleep Apnea
+1 more
COMPLETED
Evaluating the Relationship Between Sleep-Disordered Breathing and Daytime Alertness
NCT00393913
Sleep Apnea, Obstructive
COMPLETED
A Prospective Multicenter Registry of Patients With Sleep Disordered Breathing Treated With DreamStation BiPAP autoSV.
NCT03421704
Central Sleep Apnea
Mixed Sleep Apnea
Cheyne-Stokes Respiration
+1 more
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) is a condition characterized by intermittent partial collapse and closure of the upper airway (UA). This leads to sleep fragmentation, oxygen desaturation, hypercarbia, and activation of the sympathetic nervous system. OSAHS is also associated with excessive daytime sleepiness, as well as other behavioral, functional, cardiovascular and cognitive dysfunction.
Continuous Positive Airway Pressure (CPAP) is the most effective treatment for the OSAHS. CPAP stabilizes the airway and prevents instability and collapse. With a stable airway, breathing continues in a normal manner, gas exchange is improved, and there is no disruption of sleep related to disturbed breathing.
CPAP is applied to the upper airway via a mask that covers the nose or the nose and mouth and reduces/eliminates sleep disordered breathing. The period of maximum susceptibility to airway collapse is at the end of exhalation and during early inhalation. During inhalation, negative pressures are generated in the airway by the normal process of ventilation (increase of thoracic volume and reduction of intra-thoracic pressure). The constant pressure of CPAP supports the airway throughout the ventilatory cycle.
In the sleep laboratory, titration of positive airway pressure is performed to determine effective CPAP pressures. During the procedure, the patient is instrumented for full polysomnography (PSG). Therapy is applied and pressure is adjusted during the course of the night to stabilize the upper airway and the breathing pattern. With conventional CPAP, a single pressure level is applied to the airway. While adequate for a majority of patients with obstructive sleep apnea, this static prescription will present challenges in certain patients and conditions.
Other forms of positive airway pressure that are approved for the treatment of OSAHS include automatically adjusting CPAP (Auto CPAP), Bi-level Positive Airway Pressure (BiPAP), and automatically adjusting BiPAP. Auto CPAP evaluates the airflow pattern and adjusts pressure to optimize airflow. Auto CPAP accommodates patients presenting with highly variable pressure requirements (e.g., sleep stage or body position dependent sleep apnea). The automatic adjustment can be used in patients for whom in-laboratory therapy titration is either delayed or impossible.
The REMStar Auto algorithm is proactive and flow-based. It evaluates the inspiratory flow and determines impending or actual flow limitation. This occurs in concert with a program of pressure adjustments designed to evaluate the pressure at which the airway is susceptible to collapse and maintains pressures slightly above the critical pressure. The patient is protected from "break-through" events with a full complement of intelligent responses to airflow events and snoring.
BiPAP therapy is another alternative. With BiPAP therapy, the patient's breathing pattern is monitored to identify the inspiratory and expiratory phases. Pressure is increased during inhalation and decreased during exhalation. The expiratory pressure (EPAP) is adjusted to prevent airway collapse and the inspiratory pressure (IPAP) is adjusted to prevent airflow limitation, hypopnea, snoring or arterial desaturation not associated with complete airway obstruction. BiPAP therapy differs from CPAP therapy, in that in addition to stabilizing the airway, inspiratory effort is assisted by the difference between the inspiratory and expiratory pressure.
Patients with OSAHS may be prescribed BiPAP therapy if CPAP therapy is not tolerated. BiPAP therapy may also be prescribed for patients with other respiratory disorders or for patients with both sleep and respiratory-related dysfunction.
Patients experiencing reduced ventilation from lung disease, neuromuscular disorders, or problems with the control of the breathing can experience nocturnal hypoventilation that is worse during sleep than it is during wakefulness. These patients are typically more complex and require more extensive evaluation and follow-up than patients suffering only from OSAHS. Patients may also be more vulnerable to loss or interruptions in treatment and often require more advanced modes and features such as alarms and timed back-up breaths.
OSAHS patients may respond to increases in CPAP or BiPAP therapy by demonstrating a shift in the nature of the apnea from obstructive to central. In these cases, patients may not receive adequate treatment with CPAP since lower pressure levels do not manage the instability of the airway leaving residual airway obstruction, while higher pressure levels are associated with CPAP emergent events. This condition is referred to as CPAP Emergent Complex Apnea.
Auto SV (Auto Servo Ventilation) is a mode of positive airway pressure used to treat obstructive and complex central sleep apnea. Its main features include:
* Normalization of ventilation by automatically adjusting IPAP pressure to achieve a target ventilation.
* Provision of timed, back-up breaths during central apneas. The optimal back-up rate is automatically determined by the device based on the patient's breathing.
* Automatic control of EPAP pressure to treat obstructive events.
Several manufacturers produce these types of devices. The algorithms used to determine the IPAP, EPAP and minimum respiratory rate are different. The largest number of these devices currently in use are the BiPAP AutoSV Advanced System One (Philips Respironics, Murrysville PA), Dreamstation BiPAP AutoSV and the VPAP (variable positive airway pressure) Adapt S7 (ResMed Corp., San Diego CA).
Adaptive Servo Ventilation (ASV) is a mode of positive airway pressure used to treat central sleep apnea and complex sleep apnea. The main features of the Auto SV mode include; normalization of ventilation by automatically adjusting IPAP to achieve and stabilize a target ventilation; provision of timed, back-up breaths during central apneas wherein the optimal back-up rate is automatically determined by the device based on the patient's breathing; and automatic control of EPAP to treat obstructive events.
The older version of the VPAP Adapt (S7) was found to lead to increased risk for all-cause mortality when compared to control group that involved medical management in patients with heart failure with reduced ejection fraction and predominantly central sleep apnea in a recent study (SERVE-HF). An accompanying editorial by Magalang and Pack suggested that the device algorithms may have played a role -- specifically, greater levels of pressure assist and associated increase in minute ventilation. This was supported by the measurements of minute ventilation delivered by the S7 device in the trial which was found to be greater than other servo-ventilation devices. Such increased levels of ventilation could potentially cause respiratory alkalosis which, in turn, could lead to QT interval prolongation and cardiac arrhythmias. The investigators recently performed a study of patient-ventilator interaction in patients with complex sleep apnea and preserved cardiac contractility (left ventricular ejection fraction \> 45%) in order to determine the performance of various ASV devices on respiratory parameters - such as minute ventilation and apnea-hypopnea index. In order to facilitate feasibility and promote safety, the investigators avoided performing the study in the target population of the SERVE-HF trial, viz., patients with predominant central sleep apnea and heart failure with reduced ejection fraction (HFreF). The investigators performed the study only on patients with preserved ejection fraction (LVEF \> 45%). In the current proposal, the investigators propose to perform the study on patients with predominantly obstructive sleep apnea and HFreF who need ASV therapy due to PAP-emergent central apneas.
In the prior study, in order to avoid intolerance to device therapy, the investigators preferred study patients who were already adherent in using servo ventilation therapy at home. The investigators will do the same in the currently proposed study. In the prior study, the investigators found that S7 device led to greater minute ventilation than other devices and that such greater levels of minute ventilation was attributable to a greater tidal volume, higher respiratory rate, and greater pressure assist. Interestingly, there was prolongation of QTc interval and a tendency for greater premature ventricular contractions in the same patients during the nights that they were exposed to the S7 device. Although the mechanistic basis for this finding is potentially attributable to excessive ventilation and related pro-arrhythmic effects of hypocapnia, the investigators had not performed measures of partial pressure of CO2 (PaCO2) in this prior study. Specifically, it is unclear whether therapy with the S7 device leads to lower PaCO2 levels than other devices and whether such effects are augmented in individuals with high loop gain (complex sleep apnea in the setting of HFreF).
Increases in minute ventilation (Ve) during wakefulness causes hypocapnia (respiratory alkalosis), which, in turn, could cause hypokalemia. Hypokalemia due to nighttime intracellular shifts in potassium ions can prolong QT interval. Conceivably, nighttime alkalosis due to excessive ventilation may lead to daytime hypokalemia and QTc prolongation through renal loss of potassium at night with consequent effects on QTc prolongation during the daytime. The observed QTc prolongation during S7 therapy was small in magnitude (\~ 20 msec), but such effects may be magnified in patients with heart failure who develop metabolic alkalosis due to loop diuretics.The investigators did not, however, measure serum potassium levels which was a study limitation. In the current proposal, the investigators will ascertain the effects of nocturnal ASV therapy on serum potassium levels. Lastly, the investigators will explore the inter-individual variability in susceptibility in measured Ve or QTc interval.
Continuous Positive Airway Pressure (CPAP) is the most effective treatment for the OSAHS. CPAP stabilizes the airway and prevents instability and collapse. With a stable airway, breathing continues in a normal manner, gas exchange is improved, and there is no disruption of sleep related to disturbed breathing.
CPAP is applied to the upper airway via a mask that covers the nose or the nose and mouth and reduces/eliminates sleep disordered breathing. The period of maximum susceptibility to airway collapse is at the end of exhalation and during early inhalation. During inhalation, negative pressures are generated in the airway by the normal process of ventilation (increase of thoracic volume and reduction of intra-thoracic pressure). The constant pressure of CPAP supports the airway throughout the ventilatory cycle.
In the sleep laboratory, titration of positive airway pressure is performed to determine effective CPAP pressures. During the procedure, the patient is instrumented for full polysomnography (PSG). Therapy is applied and pressure is adjusted during the course of the night to stabilize the upper airway and the breathing pattern. With conventional CPAP, a single pressure level is applied to the airway. While adequate for a majority of patients with obstructive sleep apnea, this static prescription will present challenges in certain patients and conditions.
Other forms of positive airway pressure that are approved for the treatment of OSAHS include automatically adjusting CPAP (Auto CPAP), Bi-level Positive Airway Pressure (BiPAP), and automatically adjusting BiPAP. Auto CPAP evaluates the airflow pattern and adjusts pressure to optimize airflow. Auto CPAP accommodates patients presenting with highly variable pressure requirements (e.g., sleep stage or body position dependent sleep apnea). The automatic adjustment can be used in patients for whom in-laboratory therapy titration is either delayed or impossible.
The REMStar Auto algorithm is proactive and flow-based. It evaluates the inspiratory flow and determines impending or actual flow limitation. This occurs in concert with a program of pressure adjustments designed to evaluate the pressure at which the airway is susceptible to collapse and maintains pressures slightly above the critical pressure. The patient is protected from "break-through" events with a full complement of intelligent responses to airflow events and snoring.
BiPAP therapy is another alternative. With BiPAP therapy, the patient's breathing pattern is monitored to identify the inspiratory and expiratory phases. Pressure is increased during inhalation and decreased during exhalation. The expiratory pressure (EPAP) is adjusted to prevent airway collapse and the inspiratory pressure (IPAP) is adjusted to prevent airflow limitation, hypopnea, snoring or arterial desaturation not associated with complete airway obstruction. BiPAP therapy differs from CPAP therapy, in that in addition to stabilizing the airway, inspiratory effort is assisted by the difference between the inspiratory and expiratory pressure.
Patients with OSAHS may be prescribed BiPAP therapy if CPAP therapy is not tolerated. BiPAP therapy may also be prescribed for patients with other respiratory disorders or for patients with both sleep and respiratory-related dysfunction.
Patients experiencing reduced ventilation from lung disease, neuromuscular disorders, or problems with the control of the breathing can experience nocturnal hypoventilation that is worse during sleep than it is during wakefulness. These patients are typically more complex and require more extensive evaluation and follow-up than patients suffering only from OSAHS. Patients may also be more vulnerable to loss or interruptions in treatment and often require more advanced modes and features such as alarms and timed back-up breaths.
OSAHS patients may respond to increases in CPAP or BiPAP therapy by demonstrating a shift in the nature of the apnea from obstructive to central. In these cases, patients may not receive adequate treatment with CPAP since lower pressure levels do not manage the instability of the airway leaving residual airway obstruction, while higher pressure levels are associated with CPAP emergent events. This condition is referred to as CPAP Emergent Complex Apnea.
Auto SV (Auto Servo Ventilation) is a mode of positive airway pressure used to treat obstructive and complex central sleep apnea. Its main features include:
* Normalization of ventilation by automatically adjusting IPAP pressure to achieve a target ventilation.
* Provision of timed, back-up breaths during central apneas. The optimal back-up rate is automatically determined by the device based on the patient's breathing.
* Automatic control of EPAP pressure to treat obstructive events.
Several manufacturers produce these types of devices. The algorithms used to determine the IPAP, EPAP and minimum respiratory rate are different. The largest number of these devices currently in use are the BiPAP AutoSV Advanced System One (Philips Respironics, Murrysville PA), Dreamstation BiPAP AutoSV and the VPAP (variable positive airway pressure) Adapt S7 (ResMed Corp., San Diego CA).
Adaptive Servo Ventilation (ASV) is a mode of positive airway pressure used to treat central sleep apnea and complex sleep apnea. The main features of the Auto SV mode include; normalization of ventilation by automatically adjusting IPAP to achieve and stabilize a target ventilation; provision of timed, back-up breaths during central apneas wherein the optimal back-up rate is automatically determined by the device based on the patient's breathing; and automatic control of EPAP to treat obstructive events.
The older version of the VPAP Adapt (S7) was found to lead to increased risk for all-cause mortality when compared to control group that involved medical management in patients with heart failure with reduced ejection fraction and predominantly central sleep apnea in a recent study (SERVE-HF). An accompanying editorial by Magalang and Pack suggested that the device algorithms may have played a role -- specifically, greater levels of pressure assist and associated increase in minute ventilation. This was supported by the measurements of minute ventilation delivered by the S7 device in the trial which was found to be greater than other servo-ventilation devices. Such increased levels of ventilation could potentially cause respiratory alkalosis which, in turn, could lead to QT interval prolongation and cardiac arrhythmias. The investigators recently performed a study of patient-ventilator interaction in patients with complex sleep apnea and preserved cardiac contractility (left ventricular ejection fraction \> 45%) in order to determine the performance of various ASV devices on respiratory parameters - such as minute ventilation and apnea-hypopnea index. In order to facilitate feasibility and promote safety, the investigators avoided performing the study in the target population of the SERVE-HF trial, viz., patients with predominant central sleep apnea and heart failure with reduced ejection fraction (HFreF). The investigators performed the study only on patients with preserved ejection fraction (LVEF \> 45%). In the current proposal, the investigators propose to perform the study on patients with predominantly obstructive sleep apnea and HFreF who need ASV therapy due to PAP-emergent central apneas.
In the prior study, in order to avoid intolerance to device therapy, the investigators preferred study patients who were already adherent in using servo ventilation therapy at home. The investigators will do the same in the currently proposed study. In the prior study, the investigators found that S7 device led to greater minute ventilation than other devices and that such greater levels of minute ventilation was attributable to a greater tidal volume, higher respiratory rate, and greater pressure assist. Interestingly, there was prolongation of QTc interval and a tendency for greater premature ventricular contractions in the same patients during the nights that they were exposed to the S7 device. Although the mechanistic basis for this finding is potentially attributable to excessive ventilation and related pro-arrhythmic effects of hypocapnia, the investigators had not performed measures of partial pressure of CO2 (PaCO2) in this prior study. Specifically, it is unclear whether therapy with the S7 device leads to lower PaCO2 levels than other devices and whether such effects are augmented in individuals with high loop gain (complex sleep apnea in the setting of HFreF).
Increases in minute ventilation (Ve) during wakefulness causes hypocapnia (respiratory alkalosis), which, in turn, could cause hypokalemia. Hypokalemia due to nighttime intracellular shifts in potassium ions can prolong QT interval. Conceivably, nighttime alkalosis due to excessive ventilation may lead to daytime hypokalemia and QTc prolongation through renal loss of potassium at night with consequent effects on QTc prolongation during the daytime. The observed QTc prolongation during S7 therapy was small in magnitude (\~ 20 msec), but such effects may be magnified in patients with heart failure who develop metabolic alkalosis due to loop diuretics.The investigators did not, however, measure serum potassium levels which was a study limitation. In the current proposal, the investigators will ascertain the effects of nocturnal ASV therapy on serum potassium levels. Lastly, the investigators will explore the inter-individual variability in susceptibility in measured Ve or QTc interval.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Sleep Apnea, Mixed
Heart Failure
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Participants will receive three (3) randomized PSG's during which they will receive treatment from the following devices in a randomized manner:
* FDA released Philips BiPAP AutoSV Advanced System One
* FDA released Philips Dreamstation BiPAP AutoSV
* FDA released ResMed S7 VPAP Adapt
* FDA released Philips BiPAP AutoSV Advanced System One
* FDA released Philips Dreamstation BiPAP AutoSV
* FDA released ResMed S7 VPAP Adapt
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
There will be no masking involved in this study.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BiPAP AutoSV Advanced System One
Group Type
EXPERIMENTAL
BiPAP AutoSV Advanced System One
Intervention Type
DEVICE
A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.
Dreamstation BiPAP AutoSV
Group Type
EXPERIMENTAL
Dreamstation BiPaP AutoSV
Intervention Type
DEVICE
A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.
ResMed S7 VPAP Adapt device
Group Type
ACTIVE_COMPARATOR
ResMed S7 VPAP Adapt Device
Intervention Type
DEVICE
A mode of positive airway pressure used to treat sleep apnea. This device is widely used by physicians to treat sleep apnea and will be the active comparator to the two experimental devices.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BiPAP AutoSV Advanced System One
A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.
Intervention Type
DEVICE
Dreamstation BiPaP AutoSV
A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.
Intervention Type
DEVICE
ResMed S7 VPAP Adapt Device
A mode of positive airway pressure used to treat sleep apnea. This device is widely used by physicians to treat sleep apnea and will be the active comparator to the two experimental devices.
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to provide consent
* Currently prescribed servo ventilation therapy at home
* At least two weeks of recent adherence and efficacy data from PAP device demonstrating adequate use of therapy (at least 4 hours of use per night and use on at least 10 of 14 nights)
* Individuals with complex sleep apnea (obstructive sleep apnea with central apneas) and preserved left-ventricular ejection fraction (LVEF \> 45%) and/or heart failure with preserved ejection fraction (HFrEF) who are currently on ASV therapy.
* Individuals with complex sleep apnea (predominantly obstructive sleep apnea with central apneas) and reduced left-ventricular ejection fraction (LVEF \< 45%) and/or heart failure with reduced ejection fraction (HFrEF) who are currently on ASV therapy.
* Currently prescribed servo ventilation therapy at home
* At least two weeks of recent adherence and efficacy data from PAP device demonstrating adequate use of therapy (at least 4 hours of use per night and use on at least 10 of 14 nights)
* Individuals with complex sleep apnea (obstructive sleep apnea with central apneas) and preserved left-ventricular ejection fraction (LVEF \> 45%) and/or heart failure with preserved ejection fraction (HFrEF) who are currently on ASV therapy.
* Individuals with complex sleep apnea (predominantly obstructive sleep apnea with central apneas) and reduced left-ventricular ejection fraction (LVEF \< 45%) and/or heart failure with reduced ejection fraction (HFrEF) who are currently on ASV therapy.
Exclusion Criteria
* Participants who are acutely ill, medically complicated or who are medically unstable
* Participants in whom PAP therapy is otherwise medically contraindicated
* Participants who are claustrophobic
* Symptomatic ("Symptomatic" defined as hospitalized for heart failure or a change in cardiac medications, within the last two months) chronic heart failure (NYHA 2-4) AND moderate to severe predominant central sleep apnea
* Participants with previously diagnosed respiratory failure or respiratory insufficiency and who are known to have elevated arterial carbon dioxide levels while awake (PaCO2 ≥ 55mmHg).
* Participants requiring any kind of oxygen therapy
* Participants who have had surgery of the upper airway, nose, sinus, eyes, or middle ear within the previous 90 days.
* Participants in whom PAP therapy is otherwise medically contraindicated
* Participants who are claustrophobic
* Symptomatic ("Symptomatic" defined as hospitalized for heart failure or a change in cardiac medications, within the last two months) chronic heart failure (NYHA 2-4) AND moderate to severe predominant central sleep apnea
* Participants with previously diagnosed respiratory failure or respiratory insufficiency and who are known to have elevated arterial carbon dioxide levels while awake (PaCO2 ≥ 55mmHg).
* Participants requiring any kind of oxygen therapy
* Participants who have had surgery of the upper airway, nose, sinus, eyes, or middle ear within the previous 90 days.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Philips Respironics
INDUSTRY
Sponsor Role
collaborator
University of Arizona
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sairam Parthasarathy, MD
Role: PRINCIPAL_INVESTIGATOR
University of Arizona
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ASV0000001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Quality of Sleep of Patients With Predominant Central Sleep Apnea Syndrome(SAS) Whose EF > 45% Treated by ASV
NCT02835638
ACTIVE_NOT_RECRUITING
Reversible Effect of Falling Ventilatory Drive in Drive-dependent OSA
NCT06091098
RECRUITING
NA
Adaptive Servo-ventilation Monitoring Study
NCT02133859
COMPLETED
Self-Management of Continuous Positive Airway Pressure Settings
NCT03536572
COMPLETED
NA
Sleep Disordered Breathing and Chronic Pain
NCT01457014
COMPLETED
NA
ASV Effects on Myocardial Energetics and Sympathetic Nerve Function in Heart Failure and Sleep Apnea.
NCT02116140
ACTIVE_NOT_RECRUITING
NA
Evaluation of Software Enhancements to the Respironics BiPAP Auto Servo Ventilation (AutoSV) Device
NCT00720213
COMPLETED
NA
Combined Upper-airway and Breathing Control Therapies for Obstructive Sleep Apnea
NCT03189173
COMPLETED
PHASE2
Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)
NCT04179981
RECRUITING
NA
Evaluation of a Portable Device for Assessing Sleep Disordered Breathing in Congestive Heart Failure
NCT00493948
COMPLETED
Benefit of Cheyne-Stokes Respiration Remote Monitoring in CPAP-treated Patients With Obstructive Sleep Apnea to Detect Early Events of Heart Failure.
NCT03592108
COMPLETED
NA
"Reversibility of Cardiovascular Injury With CPAP Use: Mechanisms Involved"
NCT01317329
COMPLETED
NA
Sleep Apnea-hypopnea Syndrome (SAHS) and Ventricular Arrhythmias
NCT00765713
COMPLETED
PHASE4
The Role of Sleep Disordered Breathing in Heart Failure Admissions
NCT02505867
TERMINATED
NA
Effectiveness of Adaptive Servoventilation (ASV) in Patients With Central Sleep Apnea Due to Chronic Opioid Use
NCT01462084
COMPLETED
NA
Validation of a New Automatic Bi-level Algorithm in the Treatment of Sleep-disordered Breathing
NCT00910195
COMPLETED
NA
The Effects of Obstructive Sleep Apnea and Its Intervention on Coronary Heart Disease
NCT02059993
COMPLETED
NA
Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea to Prevent Cardiovascular Disease
NCT00738179
UNKNOWN
PHASE3
A Pilot Study to Assess the Effects of a Novel Application of Averaged Volume Assured Pressure Support Ventilation (AVAPS-AE) Therapy on Re-hospitalization in Patients With Sleep-Disordered Breathing With Co-morbid COPD
NCT02446769
TERMINATED
NA
Sleep Apnea Intervention for Cardiovascular Disease Reduction
NCT01261390
COMPLETED
NA
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
NCT05237505
RECRUITING
PHASE2
Effects of CPAP Therapy on Blood Pressure and Heart Rate Variability in Obstructive Sleep Apnea
NCT04712656
RECRUITING
Impact of Early Ventilation in Stroke Outcomes in Patients With Sleep Apnea After First Ever Stroke
NCT04903951
RECRUITING
PHASE2
Treatment of Sleep Disordered Breathing In Acute Decompensated Heart Failure Patients
NCT00804349
COMPLETED
PHASE4